N-((2S)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3- dimethyl-L-Valinamide: matrix metalloproteinase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9913881 |
| CHEMBL ID | 76222 |
| SCHEMBL ID | 645121 |
| MeSH ID | M0381870 |
| Synonym |
|---|
| d-2163 |
| CHEMBL76222 , |
| bms-275291-01 |
| bms 275291-01 |
| bms-275291 |
| D03800 |
| rebimastat (usan/inn) |
| 259188-38-0 |
| d 2163 |
| rebimastat |
| 2-[2-mercapto-4-(3,4,4-trimethyl-2,5-dioxo-imidazolidin-1-yl)-butyrylamino]-4-methyl-pentanoic acid (2,2-dimethyl-1-methylcarbamoyl-propyl)-amide(bms-275291) |
| bdbm50108168 |
| D2163 , |
| l-valinamide, n-((2s)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3-dimethyl- |
| (2s)-n-((1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl)-4-methyl-2-(((2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl)amino)pentanamide |
| 1b47r6zx4k , |
| n-((2s)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3-dimethyl-l-valinamide |
| n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide |
| rebimastat [usan:inn] |
| unii-1b47r6zx4k |
| bms 275291 |
| rebimastat [usan] |
| rebimastat [who-dd] |
| (2s)-n-[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide |
| rebimastat [inn] |
| SCHEMBL645121 |
| DB06573 |
| bms 275291-01; d 2163; rebimastat |
| (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide |
| Q27252183 |
| l-valinamide, n-[(2s)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl]-l-leucyl-n,3-dimethyl- |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat, which bind covalently to the zinc atom at the MMP-active site, were the first MMP inhibitors to be studied in detail." | ( Development of matrix metalloproteinase inhibitors in cancer therapy. Eckhardt, SG; Hidalgo, M, 2001) | 0.31 |
| " Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models." | ( Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. Albert, DH; Bouska, JJ; Curtin, ML; Dai, Y; Davidsen, SK; Elmore, IN; Florjancic, AS; Garland, RB; Goodfellow, CL; Guo, Y; Heyman, HR; Holms, JH; Marcotte, PA; Michaelides, MR; Morgan, DW; Stacey, JR; Steinman, DH; Tapang, P; Wada, CK, 2002) | 0.31 |
| " The safety and efficacy of a novel, orally bioavailable MMP inhibitor, BMS-275291, was evaluated in patients with human immunodeficiency virus-associated KS and the correlation between changes in the percentage of apoptotic cells in tumor biopsies and response was explored." | ( Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Brinker, BT; Cesarman, E; Chadburn, A; Henry, DH; Kaplan, LD; Krown, SE; Lee, JY; Von Roenn, JH, 2008) | 0.35 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Interstitial collagenase | Homo sapiens (human) | IC50 (µMol) | 0.0250 | 0.0002 | 0.8502 | 10.0000 | AID109078 |
| 72 kDa type IV collagenase | Homo sapiens (human) | IC50 (µMol) | 0.0410 | 0.0000 | 1.2848 | 10.0000 | AID107333 |
| Stromelysin-1 | Homo sapiens (human) | IC50 (µMol) | 0.1570 | 0.0000 | 1.1484 | 10.0000 | AID107675 |
| Matrix metalloproteinase-9 | Homo sapiens (human) | IC50 (µMol) | 0.0250 | 0.0000 | 0.7053 | 10.0000 | AID108303 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID107675 | Inhibition of Matrix metalloprotease-3 (MMP-3) in fluorimetric assay | 2002 | Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1 | Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. |
| AID108303 | In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay | 2002 | Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1 | Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. |
| AID109078 | In vitro selective inhibition against matrix metalloprotease-1 (MMP-1) using a fluorimetric assay | 2002 | Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1 | Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. |
| AID107333 | In vitro selective inhibition against matrix metalloprotease-2 (MMP-2) using fluorimetric assay | 2002 | Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1 | Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (46.67%) | 5.53% |
| Reviews | 4 (26.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (26.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||